β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease

被引：67

作者：

Andreasen, N ^{[1
]}

Blennow, K

机构：

[1] Huddinge Univ Hosp, Karolinska Inst, Neurotec, Dept Geriatr Med, SE-14186 Stockholm, Sweden

[2] Univ Gothenburg, Dept Clin Neurosci, Unit Neurochem, Gothenburg, Sweden

[3] MRC, Stockholm, Sweden

来源：

PEPTIDES | 2002年 / 23卷 / 07期

关键词：

Alzheimer's disease (AD); beta-amyloid (A beta); biochemical markers; cerebrospinal fluid (CSF); plasma; diagnosis;

D O I：

10.1016/S0196-9781(02)00056-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With the arrival of symptomatic treatment (acetylcholine esterase inhibitors) and the promise of drugs that may delay disease progression, development of diagnostic biomarkers for Alzheimer's disease (AD) are important. beta-Amyloid (Abeta) protein is the main component of senile plaques. A marked reduction in cerebrospinal nuid (CSF)-Abeta42 in AD has been found in numerous studies. Importantly, reduced CSF-Abeta42 is also found very early in the disease process, before the onset of clinical symptoms. Recent studies suggest that CSF-Abeta42 have a satisfactory performance when used as a diagnostic marker for AD in clinical routine. This paper reviews CSF-Abeta42 as a biomarker for AD. (C) 2002 Elsevier Science Inc. All rights reserved.

引用

页码：1205 / 1214

页数：10

共 100 条

[1] Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
[2] Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715→Met βAPP-770 mutation responsible for probable early-onset Alzheimer's disease
Ancolio, K
Dumanchin, C
Barelli, H
Warter, JM
Brice, A
Campion, D
Frébourg, T
Checler, F
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) : 4119 - 4124
[3] Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
Andreasen, N
Minthon, L
Vanmechelen, E
Vanderstichele, H
Davidsson, P
Winblad, B
Blennow, K
[J]. NEUROSCIENCE LETTERS, 1999, 273 (01) : 5 - 8
[4] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
Andreasen, N
Hesse, C
Davidsson, P
Minthon, L
Wallin, A
Winblad, B
Vanderstichele, H
Vanmechelen, E
Blennow, K
[J]. ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 673 - 680
[5] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N
Minthon, L
Davidsson, P
Vanmechelen, E
Vanderstichele, H
Winblad, B
Blennow, K
[J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 373 - 379
[6] Serpents on the road to dementia and death
Beyreuther, K
Masters, CL
[J]. NATURE MEDICINE, 1997, 3 (07) : 723 - 725
[7] Genetic testing for Alzheimer's disease: how close is reality?
Blennow, K
Skoog, I
[J]. CURRENT OPINION IN PSYCHIATRY, 1999, 12 (04) : 487 - 493
[8] BLENNOW K, 1993, ACTA NEUROL SCAND, V88, P221
[9] Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor
Buxbaum, JD
Liu, KN
Luo, YX
Slack, JL
Stocking, KL
Peschon, JJ
Johnson, RS
Castner, BJ
Cerretti, DP
Black, RA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) : 27765 - 27767
[10] EARLY-ONSET ALZHEIMERS-DISEASE CAUSED BY MUTATIONS AT CODON-717 OF THE BETA-AMYLOID PRECURSOR PROTEIN GENE
CHARTIERHARLIN, MC
CRAWFORD, F
HOULDEN, H
WARREN, A
HUGHES, D
FIDANI, L
GOATE, A
ROSSOR, M
ROQUES, P
HARDY, J
MULLAN, M
[J]. NATURE, 1991, 353 (6347) : 844 - 846

← 1 2 3 4 5 6 7 8 9 10 →